Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

4.08
-0.1900-4.45%
Post-market: 4.130.0500+1.23%19:57 EDT
Volume:547.18K
Turnover:2.17M
Market Cap:6.66M
PE:-0.22
High:4.70
Open:3.79
Low:3.65
Close:4.27
52wk High:71.50
52wk Low:3.18
Shares:1.63M
Float Shares:1.20M
Volume Ratio:33.38
T/O Rate:45.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:2.08
PE(LYR):-0.07

Loading ...

Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics - to Advance Erna-101 Toward Ind Submission for Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics - Clinical Data from Erna-101 Proc Study Expected in Q4 2027

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics - Pauses Additional Preclinical Development Expenditures on Erna-201

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing

GlobeNewswire
·
Yesterday

Ernexa Therapeutics CEO Sanjeev Luther Presents at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 14

Ernexa Therapeutics Director David Polinsky Files Initial Beneficial Ownership Statement

Reuters
·
Aug 28

Ernexa Therapeutics Posts On-Demand Video Webcast of Investor Presentation

Reuters
·
Aug 27

Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Dow Jones
·
Aug 10

Ernexa Therapeutics Inc Expected to Post a Loss of $3.84 a Share - Earnings Preview

Reuters
·
Aug 08

Ernexa Q2 Net Loss Widens to $4.01 Million; Reports no Revenue

Reuters
·
Aug 07

Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors

Reuters
·
Jul 24

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

GlobeNewswire
·
Jul 24

NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am

Reuters
·
Jul 15

Ernexa Therapeutics announces new ERNA-101 preclinical data

TIPRANKS
·
Jul 15

Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study

Reuters
·
Jul 15

Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026

THOMSON REUTERS
·
Jul 15